drugset / Trial / NCT01086449

Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults

NCT01086449 ↗

Phase 1 Completed 20 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in healthy ethnic Japanese adults.

Timeline

Start
2010-03-04
Primary completion
2010-06-25
Completion
2010-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Shingrix Vaccine — Intramuscular

Indications